Wall Street's major averages dipped for the week as investors wrestled with tariff twists from the Trump administration. The S&P 500 Health Care Index Sector (XLV) was also down 0.29% during the week.

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic Helfgott, said in an interview.

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive dynamic of the U.